

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

1. (original) A method for identifying a compound useful for modulating angiogenesis, the method comprising the steps of: a) contacting a test compound with a HB-954 polypeptide; and b) determining whether the test compound binds to the HB-954 polypeptide.
2. (original) The method of claim 1, wherein the binding to the HB-954 polypeptide is within a  $K_D$  range of  $10e^{-6}$  to  $10e^{-13}$  preferably within a range of  $10e^{-8}$  to  $10e^{-12}$ .
3. (currently amended) The method of claim 1 ~~or~~ 2, said method further comprising the steps of: c) adding a compound identified as binding to the HB-954 polypeptide in step (b) to an assay for the modulation of angiogenesis; d) determining whether the compound modulates angiogenesis; and e) identifying a compound that modulates angiogenesis in step (d) as a compound useful for the treatment of angiogenesis related diseases.
4. (original) A method for identifying a compound useful for modulating angiogenesis, the method comprising: a) contacting a HB-954 ligand with a HB-954 polypeptide in the presence and absence of a test compound; and b) determining whether the test compound alters the binding of the HB-954 ligand to the HB-954 polypeptide.
5. (original) The method of claim 4, said method further comprising the steps of: c) adding a compound identified that alters binding of the HB-954 ligand to the HB-954 polypeptide in step (b) to an assay for the modulation of angiogenesis; d) determining whether the compound modulates angiogenesis; and e) identifying a compound that modulates angiogenesis in step (d) as a compound useful for the treatment of angiogenesis related diseases.
6. (currently amended) The method of ~~any of~~ claims 1 ~~to~~ 5, wherein the HB-954 polypeptide is expressed on the surface of a recombinant cell.
7. (original) The method of claim 6, wherein said recombinant cell is an eukaryotic cell.
8. (original) A method for identifying a compound useful for modulating angiogenesis, the method comprising: a) contacting a test compound with a cell expressing a HB 954 polypeptide; and b) determining whether the test compound alters activity of the HB-954 polypeptide in said cell;

9. (original) The method of claim 8, said method further comprising the steps of: c) adding a compound identified that alters the activity of the HB-954 polypeptide in step (b) to an assay for the modulation of angiogenesis; d) determining whether the I compound modulates angiogenesis; and e) identifying a compound that modulates angiogenesis in step (d) as a compound useful for the treatment of angiogenesis related diseases.
10. (currently amended) The method of claim 1, ~~4 or 8~~, wherein modulation of angiogenesis is inhibition of angiogenesis.
11. (currently amended) The method of claim 1, ~~4 or 8~~, wherein modulation of angiogenesis is activation of angiogenesis.
12. (currently amended) The method of claim 8 ~~or 9~~, wherein the activity of the HB-954 polypeptide is determined by measuring the level of cAMP in the cell.
13. (currently amended) The method of claim 8 ~~or 9~~, wherein the activity of the HB-954 polypeptide is determined by measuring the level of cytoplasmic  $\text{Ca}^{2+}$  in the cell.
14. (currently amended) The method of claim 8 ~~or 9~~ wherein which the cell further contains a reporter gene operatively associated with a cAMP responsive element, and the level of cAMP is measured by measuring expression of the reporter gene.
15. (currently amended) The method of claim 8 ~~or 9~~ wherein the activity of the HB-954 polypeptide is measured by measuring intracellular inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ).
16. (currently amended) The method of claim 8 ~~or 9~~ wherein the activity of HB-954 is measured by measuring intracellular 1,2-diacylglycerol (DAG).
17. (original) A pharmaceutical formulation for the modulation of angiogenesis, comprising a compound that modulates the activity of HB-954, mixed with a pharmaceutically acceptable carrier.
18. (original) A package comprising the pharmaceutical formulation of claim 17 and instructions for administering the pharmaceutical formulation for the purpose of modulating angiogenesis.
19. (original) A gene therapy vector comprising a nucleic acid molecule that encodes HB-954 protein or a biologically active fragment thereof.
20. (original) A nucleic acid molecule that is complementary to a nucleic acid molecule that encodes HB-954 protein or a fragment thereof.

21. (original) A gene therapy vector comprising the nucleic acid molecule of claim 20.
22. (original) The use of HB-954 protein or a biologically active fragment thereof in medicine.
23. (original) The use of a monoclonal antibody which specifically binds an epitope of HB-954 protein or a biologically active fragment thereof in medicine.